Is Perrigo (PRGO) Undervalued After Its 2026 Sales Guidance Cut?
Perrigo (PRGO) updated its 2026 sales guidance, expecting a 5.7% to 4.6% year-over-year decline. The company reaffirmed its quarterly dividend, and its share price has risen 23.4% over the past 90 days to $15.85. Analysts have a consensus price target of $18, with estimates ranging from $15 to $20. Investors are evaluating whether the stock is undervalued given recent performance and guidance.
How this was made
The 30-second read
Why it matters
The guidance cut is the primary new fact; prior performance and price targets are recapped.
Market read
First disclosure of 2026 sales guidance cut, likely prompting short‑term price adjustment.
What to watch
Potential cost‑cutting measures or new product launches not discussed may mitigate the impact of the sales decline.
Background
The article reviews Perrigo's recent performance, highlights its share price rally, and frames the new guidance as a valuation catalyst.
Ticker impact
Perrigo disclosed 2026 sales guidance cut to a 4.6%-5.7% YoY decline, the first report of this guidance in the article.
downward pressure as investors price in weaker sales outlook
The new mid‑single‑digit sales contraction is a material downgrade to expectations and may trigger sell‑offs.
Market effects
Healthcare self‑care segment may see broader valuation pressure as peers face similar sales headwinds.
U.S. listed healthcare stocks could experience modest downside.
Limited to investors tracking U.S. consumer health companies.
Counterpoint
If the dividend remains intact and short‑term momentum continues, the stock could hold or rebound despite lower guidance.
Key entities
- CompanyPerrigo
U.S. self‑care healthcare company (ticker PRGO).
